595 related articles for article (PubMed ID: 18366924)
21. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
23. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Drenberg CD; Saunders BO; Wilbanks GD; Chen R; Nicosia RF; Kruk PA; Nicosia SV
Gynecol Oncol; 2010 Apr; 117(1):117-24. PubMed ID: 20071014
[TBL] [Abstract][Full Text] [Related]
24. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor and psychosocial factors in colorectal cancer.
Sharma A; Greenman J; Sharp DM; Walker LG; Monson JR
Psychooncology; 2008 Jan; 17(1):66-73. PubMed ID: 17410522
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
Oehler MK; Caffier H
Anticancer Res; 2000; 20(6D):5109-12. PubMed ID: 11326678
[TBL] [Abstract][Full Text] [Related]
27. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
29. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
30. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
31. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
32. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
33. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
36. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
38. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
Poon RT; Lau C; Yu WC; Fan ST; Wong J
Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
[TBL] [Abstract][Full Text] [Related]
39. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer.
Kimura H; Kato H; Tanaka N; Inose T; Faried A; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2008; 28(1A):165-9. PubMed ID: 18383841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
